Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update.

IF 1.3 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-06-17 DOI:10.1080/20450923.2025.2516994

Shiguang Chen, Wenchang Yu, Xiaolong Wang, Weifu Liu

{"title":"Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update.","authors":"Shiguang Chen, Wenchang Yu, Xiaolong Wang, Weifu Liu","doi":"10.1080/20450923.2025.2516994","DOIUrl":null,"url":null,"abstract":"Aims: Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.Methods: In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin.Results: The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively.Conclusion: The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC.Clinical trial registration: www.chictr.org.cn identifier is ChiCTR-OOC-17014182.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2516994"},"PeriodicalIF":1.3000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184121/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20450923.2025.2516994","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.

Methods: In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin.

Results: The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively.

Conclusion: The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC.

Clinical trial registration: www.chictr.org.cn identifier is ChiCTR-OOC-17014182.

查看原文本刊更多论文

肝动脉输注化疗在不可切除的肝细胞癌患者中的应用：3年生存更新。

目的：在一项2期试验中，奥沙利铂加雷曲塞肝动脉输注化疗（HAIC）在不可切除的肝细胞癌（HCC）患者中显示出良好的反应率。在这里，我们报告了入组后更新的3年生存数据。方法：在这项前瞻性试验中，我们招募了中晚期不可切除的HCC患者。治疗为雷曲塞加奥沙利铂的HAIC。结果：在意向治疗人群中，39例患者中有19例（48.7%）实现了客观缓解。中位总生存期和无进展生存期分别为11.2个月和6.5个月。结论：3年生存期更新证实了HAIC联合奥沙利铂+雷曲塞治疗不可切除HCC患者的抗肿瘤活性和长期生存获益。临床试验注册：www.chictr.org.cn标识符为ChiCTR-OOC-17014182。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.